Representative KRAS-directed combination therapy trials are shown that have completed accrual, are currently open or are awaiting activation. † Clinicaltrials.gov identifier. RAF, PI3K and the ...

In 5–10 years, data from the second generation of clinical trials targeting KRAS downstream signaling pathways will have emerged, incorporating novel therapeutic approaches such as the ...